Carfilzomib therapy for relapsed myeloma: results of a UK multicentre experience

Djebbari, Faouzi; Hubenov, H.; Neelakantan, Pratap; Wolf, Julia; Offer, Mark; Khera, Akhil; Vallance, Grant; Kothari, Jaimal; Moore, Sally; Ramasamy, Karthik

doi:10.1111/bjh.16324

Cited by 2 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For patients treated with carfilzomib plus dexamethasone (CarDex) at first relapse and are tolerating it well, reducing dose intensity from twice‐weekly to once‐weekly prior to achieving a significant response will reduce hospital visits, but could result in a reduced depth of response 17 …”

Section: The Relapsed Multiple Myeloma (Rmm) Settingmentioning

confidence: 99%

Myeloma care adaptations in the UK during SARS‐CoV‐2 pandemic: Challenges and measurable outcomes

Djebbari

Panitsas

Sharpley

et al. 2020

European J of Haematology

Self Cite

View full text Add to dashboard Cite

To the Editor, Following the emergence of COVID-19 as a global pandemic, cancer clinicians have been faced with the challenge of continuing to manage patients, with limited data to inform practice. 1 Recently, a largeprospective cohort study of 800 cancer patients diagnosed with symptomatic COVID-19 demonstrated a mortality rate of 28%, which was largely driven by age, co-morbidities and being a male. 2 Patients with plasma cell dyscrasias (PCD), in particular, are known to be at a high risk of infections, in part due to immunoparesis and immunosuppressive therapy. Old age, frailty and co-morbidities add to the complexity of patient management. COVID-19 poses a significant new threat to their health and wellbeing. There is currently little evidence to suggest how myeloma patients will respond to this infection. The UK government recommended that myeloma patients shield for an initial 12-week period, because they fall in the extremely vulnerable group. 3 A UK retrospective real-world audit of 75 myeloma patients with symptomatic COVID-19 demonstrated a high mortality rate especially in patients aged >80 years. 4

show abstract

Section: The Relapsed Multiple Myeloma (Rmm) Settingmentioning

confidence: 99%